Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies (Q37993779)

26 August 2017

title

Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

26 August 2017

0 references

0 references

1 reference

1 reference

William Nseir

1

1 reference

26 August 2017

Julnar Mograbi

series ordinal

2

1 reference

26 August 2017

Murad Ghali

series ordinal

3

1 reference

26 August 2017

publication date

15 March 2012

1 reference

Digestive Diseases and Sciences

26 August 2017

published in

1 reference

26 August 2017

volume

57

1 reference

26 August 2017

issue

7

1 reference

26 August 2017

page(s)

1773-1781

1 reference

https://scigraph.springernature.com/pub.10.1007/s10620-012-2118-3

26 August 2017

exact match

0 references

cites work

Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Nonalcoholic fatty liver disease and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Body fat topography as an independent predictor of fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Insulin effects on sterol regulatory-element-binding protein-1c (SREBP-1c) transcriptional activity in rat hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Steatohepatitis: a tale of two "hits"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Apolipoprotein synthesis in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Fatty infiltration of liver in hyperlipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Decreased survival of subjects with elevated liver function tests during a 28-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Use of statins in patients with liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Overproduction of large VLDL particles is driven by increased liver fat content in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Soft drinks consumption and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Nonalcoholic fatty liver disease: the potential role of nutritional management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Review: The role of insulin resistance in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Statins as anti-inflammatory agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Long-term statin therapy affects the severity of chronic gastritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Beyond the laboratory: clinical implications for statin pleiotropy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Effects of 1-O-hexyl-2,3,5-trimethylhydroquinone on carbon tetrachloride-induced hepatic cirrhosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Hyperbaric oxygen therapy for diabetic foot wounds: has hope hurdled hype?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Fish oil prevents insulin resistance induced by high-fat feeding in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Peroxisome Proliferator-Activated Receptors, Fatty Acid Oxidation, Steatohepatitis and Hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

Lipid-lowering agents that cause drug-induced hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2118-3

American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease

21 January 2018

1 reference

12 December 2020

The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis

1 reference

12 December 2020

In Vivo Stimulation of Low-Density Lipoprotein Degradation by Insulin

1 reference

12 December 2020

A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis

1 reference

12 December 2020

Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome

1 reference

12 December 2020

Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease

1 reference

12 December 2020

Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial

1 reference

12 December 2020

Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study

1 reference

12 December 2020

Effects of lovastatin and pentoxyphyllin in nonalcoholic steatohepatitis.

1 reference

12 December 2020

A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients

1 reference

12 December 2020

National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1 reference

12 December 2020

Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet

1 reference

12 December 2020

Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia

1 reference

12 December 2020

Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study

1 reference

12 December 2020

Clinical inquiries. What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterol-lowering agents?

1 reference

12 December 2020

Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease.

1 reference

12 December 2020

Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study

1 reference

12 December 2020

The impact of prior long-term versus short-term statin use on the mortality of bacteraemic patients

1 reference

12 December 2020

10.1007/S10620-012-2118-3

Identifiers

DOI

1 reference

26 August 2017

1 reference